市場調査レポート
商品コード
1114740

経腸栄養剤の世界市場:製品別 (高分子、エレメンタル、特定疾患向け)・段階別 (成人、小児)・用途別 (腫瘍、消化器、神経、代謝亢進)・エンドユーザー別 (病院、長期介護施設 (LTCF)、在宅介護) の将来予測 (2027年まで)

Enteral Feeding Formulas Market by Product (Polymeric, Elemental, Disease-specific), Stage (Adults, Pediatrics), Application (Oncology, Gastroenterology, Neurology, Hypermetabolism), End User (Hospitals, LTCF, Home care) - Global Forecast to 2027

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 224 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
経腸栄養剤の世界市場:製品別 (高分子、エレメンタル、特定疾患向け)・段階別 (成人、小児)・用途別 (腫瘍、消化器、神経、代謝亢進)・エンドユーザー別 (病院、長期介護施設 (LTCF)、在宅介護) の将来予測 (2027年まで)
出版日: 2022年08月10日
発行: MarketsandMarkets
ページ情報: 英文 224 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

経腸栄養剤の世界市場は、2022年の52億米ドルから2027年には82億米ドルに達し、予測期間中に9.5%のCAGRで成長すると予測されています。

経腸栄養剤は、非経口栄養法など従来の栄養投与方法に比べてさまざまな利点があることから、長年にわたって医療業界で重要視されてきました。医療費の増加、早産児の急増、高齢化社会の進展、糖尿病、がん、消化器疾患、神経疾患などの慢性疾患の増加、経腸栄養に対する意識の高まり、新興国における医療施設の急速な改善などの要因が、予測期間中に市場をさらに牽引すると考えられています。さらに、非経口栄養から経腸栄養への移行や、長期介護施設における経腸栄養剤の導入と需要の増加も、今後数年間で市場を牽引すると予想されます。

"製品別では、予測期間中、標準処方の分野が最大のシェアを占める"

2021年には標準 (高分子) 処方が最も大きなシェアを占め、次いで特定疾患用処方が続いています。標準的な処方は簡単に入手でき、日々の必要量を満たすために広く使用されています。したがって、対象疾患の有病率の上昇は、標準的な処方の需要を促進する上でより大きな役割を果たします。

"用途別では、腫瘍分野が予測期間中に最も高い成長を維持する"

2021年には、腫瘍分野が最大のシェアを占め、消化器疾患、神経疾患、糖尿病、その他の用途がそれに続きました。がんの負担の増加、病院から外来診療へのシフト、がん患者における非経口栄養の効率的な代替手段としての経腸栄養の採用の高まりは、腫瘍分野での経腸栄養剤の需要を促進するものと思われます。

"年齢層別では、予測期間中、成人向けが最大のシェアを占める"

2021年には、成人患者の増加が見られ、より大きな市場シェアを占めています。これは、成人患者におけるがんの発生率が増加していることに起因しています。ほとんどのがん患者が栄養不良に苦しんでいるように、がん患者の増加は、効果的な経腸栄養の需要を増加させると予想されます。また、慢性疾患の増加は、栄養失調に起因していると老人人口の急激な増加は、市場にプラスの影響を与えています。

"エンドユーザー別では、長期介護施設は、予測期間中に高い市場シェアを保持する"

2021年、長期介護施設はより高いCAGRを維持しています。慢性疾患や障害に苦しむ患者は、疾患/障害の重症度に応じて、長期介護や在宅介護を勧められます。医療費の高騰やCOVID-19の発生を抑制するために病院への圧力が高まっているため、病院での長期治療から自宅での治療へとシフトしています。

"2021年はアジア太平洋が最も高い成長率で推移する"

予測期間中、アジア太平洋は経腸栄養剤の地域市場として最も急成長すると予測されています。老年人口の増加、高度医療施設に対する認識とアクセスの向上、医療支出の増加、主要市場プレイヤーのAPAC新興国への注力の高まり、医療保険分野の急速な改善など、いくつかの要因が市場成長の原動力となっています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
  • ポーターのファイブフォース分析
  • 規制シナリオ
  • バリューチェーン分析
  • サプライチェーン分析
  • エコシステム・市場トマップ
  • 価格分析
  • 特許分析
  • 主な会議とイベント (2022年~2023年)
  • 主な利害関係者と購入基準
  • エンドユーザーの主な購入基準

第6章 経腸栄養剤市場:段階別

  • イントロダクション
  • 成人
  • 小児

第7章 経腸栄養剤市場:製品別

  • イントロダクション
  • 標準処方
  • 特定疾患向け処方
    • 糖尿病向け処方
    • 腎臓向け処方
    • 肝臓向け処方
    • 肺向け処方
    • その他の疾患向け処方
  • ペプチドベース処方
  • その他の処方

第8章 経腸栄養剤市場:用途別

  • イントロダクション
  • 腫瘍
  • 消化器疾患
  • 神経症
  • 糖尿病
  • その他の用途

第9章 経腸栄養剤市場:エンドユーザー別

  • イントロダクション
  • 病院
  • 長期介護施設 (LTCF)
    • 高齢者福祉施設
    • 生活支援施設
    • 在宅介護機関・ホスピス

第10章 経腸栄養剤市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 他の欧州諸国
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 他のアジア太平洋諸国
  • ラテンアメリカ
  • 中東・アフリカ

第11章 競合情勢

  • 概要
  • 主要企業の戦略/有力企業
  • 市場シェア分析
  • 主要企業の収益シェア分析
  • 企業評価クアドラント
  • 競合ベンチマーキング
    • 企業のフットプリント分析
    • 企業の製品フットプリント
    • 企業の地域フットプリント
  • 競合シナリオと動向

第12章 企業プロファイル

  • 主要企業
    • ABBOTT
    • NESTLE
    • DANONE S.A.
    • FRESENIUS KABI
    • B. BRAUN MELSUNGEN AG
    • OTSUKA HOLDINGS CO., LTD.
    • NUTRITIONAL MEDICINALS, LLC
    • KATE FARMS
    • MEDTRITION INC.
    • VICTUS, INC.
    • GLOBAL HEALTH PRODUCTS, INC.
    • MEIJI HOLDINGS
    • RECKITT BENCKISER GROUP
  • その他の企業
    • HORMEL FOODS CORPORATION
    • DERMARITE INDUSTRIES
    • MEDLINE INDUSTRIES, LP
    • REAL FOOD BLENDS
    • AJINOMOTO CAMBROOKE, INC.

第13章 付録

目次
Product Code: PH 4148

The global enteral feeding formula market is projected to reach USD 8.2 billion by 2027 from USD 5.2 billion in 2022, growing at a CAGR of 9.5% during the forecast period. Over the years, enteral feeding formula have received importance in the healthcare industry, due to their various advantages over the traditional methods of nutrition administration, such as parenteral nutrition. Apart from being cost-intensive, parenteral nutrition is also associated with complications such as infections. Thus, the demand for enteral feeding formula is growing globally. Factors such as rising healthcare costs; a surge in the number of preterm births; growth in the aging population; rising prevalence of chronic diseases such as diabetes, cancer, gastrointestinal diseases, and neurological disorders; growing awareness of enteral nutrition; and rapid improvements in healthcare facilities in emerging countries are expected to further drive the market during the forecast period. Moreover, the shift from parenteral nutrition to enteral nutrition and growing adoption of and demand for enteral feeding formula in long term care facilities are also expected to drive the market in the coming years. In addition, insufficient or lack of reimbursements in some developing and underdeveloped countries and a dearth of trained physicians across the globe pose significant challenges for the growth of this market.

Based on product, the standard formula segment holds the largest share during the forecast period.

Based on product, the enteral feeding formulas market is segmented into standard (polymeric), peptide-based (elemental/semi-elemental), disease-specific, and other formulas. In 2021 standard formulas held the largest share, followed by disease-specific formulas. Standard formulas are easily available and widely used to fulfill daily requirements. The rising prevalence of target ailments thus plays a greater role in driving demand for standard formulas.

Based on application, the oncology segment holds the highest growth during the forecast period.

In 2021, the oncology segment accounted for the largest share of the enteral feeding formula market, followed by gastrointestinal diseases, neurological disorders, diabetes, and other applications. Increasing burden of cancer, the shift from hospitals to ambulatory care settings and the rising adoption of enteral feeding as an efficient alternative to parenteral nutrition among cancer patients are likely to fuel the demand for enteral feeding formulas in oncological applications.

Based on age group, the adult segment holds the largest share during the forecast period

Based on age group, the enteral feeding formula market is segmented into adult patients (18 years and over) and pediatric patients (neonates under 1 month, infants between 1 month and 2 years of age, children between 2 and 12 years, and adolescents between 12 and 16 years). In 2021, there has been a increase in adult patients accounted for a larger market share. This can be attributed to the growing incidence of cancer in adult patients, As most cancer patients suffer from malnutrition, an increase in cancer cases is expected to increase the demand for effective enteral nutrition. Also increase in chronic diseases are resulting in malnutrition and the rapid increase in the geriatric population are positively impacting market.

Based on end user, the long term care facilities holds the higher market share during the forecast period.

In 2021, Long term care facilities have a higher CAGR. Patients suffering from chronic diseases and disorders are advised long-term care or home care, depending upon the severity of the disease/disorder. Due to the increasing pressure on hospitals to curtail the soaring healthcare costs and the COVID-19 outbreak, there has been a shift from extended hospital treatment toward treatment at home. Studies reveal that home enteral nutrition (HEN) is significantly cheaper than home parenteral nutrition in the US. Growing awareness of therapeutic nutrition has contributed to the use of enteral nutrition products by patients at home.Thus end user segment registered higher market share.

APAC is expected to grow at the highest growth rate in 2021

During the forecast period, the Asia Pacific is estimated to be the fastest-growing regional market for enteral feeding formula. Several factors, such as the rising geriatric population, increased awareness of and accessibility to advanced healthcare facilities, rising healthcare spending, the growing focus of key market players on emerging APAC countries, and rapid improvements in the health insurance sector are driving the market growth.

The primary interviews conducted for this report can be categorized as follows:

  • By Company: Tier 1- 60%, Tier 2 - 30%, and Tier 3- 10%
  • By Designation: C-Level- 30%%, Director level - 50%, and Others - 20%
  • By Region: North America -45%, Europe -15%, Asia-Pacific -25%, Latin America - 10%, and Middle East and Africa - 5%

Key players in the enteral feeding formula market

Prominent players in this market include Abbott (US), Nestle S.A. (Switzerland), Danone S.A. (France), Fresenius Kabi (Germany), B. Braun Melsungen AG (Germany), Otsuka Holding Co. Ltd. (Japan), Nutritional Medicinals, LLC (US), Kate Farms (US), Medtrition Inc. (US), Victus, Inc. (US), Global Health Products, Inc. (US), Meiji Holdings Co., Ltd. (Japan), Reckitt Benckiser Group PLC. (UK), Hormel Foods Corporation (US), DermaRite Industries, LLC. (US), Medline Industries, LP. (US), Real Food Blends (US), and Ajinomoto Cambrooke, Inc. (US).

Research Coverage:

The report analyzes the enteral feeding formula market and aims at estimating the market size and future growth potential of this market based on various segments such as product, stage, application, end user and region. The report also includes a product portfolio matrix of various enteral feeding products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on product portfolios offered by the top players in the global enteral feeding formula market. The report analyzes this market by product, stage, application, end user, and region
  • Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global enteral feeding formula market
  • Market Development: Comprehensive information on the lucrative emerging markets by product type, age group, application, end user, and region
  • Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global enteral feeding formula market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global enteral feeding formula market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 STUDY SCOPE
    • FIGURE 1 ENTERAL FEEDING FORMULAS MARKET
  • 1.4 YEARS CONSIDERED
  • 1.5 CURRENCY CONSIDERED
  • 1.6 LIMITATIONS
  • 1.7 STAKEHOLDERS
  • 1.8 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 3 ENTERAL FEEDING FORMULAS MARKET: BREAKDOWN OF PRIMARIES
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF ENTERAL FEEDING FORMULAS
    • FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2021
    • FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2021
  • 2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
    • FIGURE 7 ENTERAL FEEDING FORMULAS MARKET: CAGR PROJECTIONS, 2022-2027
    • FIGURE 8 ENTERAL FEEDING FORMULAS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.5 INSIGHTS FROM PRIMARIES
    • FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS
  • 2.6 RESEARCH ASSUMPTIONS
  • 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

    • FIGURE 12 ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
    • FIGURE 13 ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 14 ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    • FIGURE 15 ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    • FIGURE 16 GEOGRAPHIC ANALYSIS: ENTERAL FEEDING FORMULAS MARKET

4 PREMIUM INSIGHTS

  • 4.1 ENTERAL FEEDING FORMULAS MARKET OVERVIEW
    • FIGURE 17 INCREASING PREVALENCE OF CHRONIC DISEASES AND SHIFT FROM PARENTERAL NUTRITION TO ENTERAL NUTRITION TO DRIVE MARKET GROWTH
  • 4.2 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET, BY TYPE (2022)
    • FIGURE 18 STANDARD FORMULAS TO DOMINATE APAC ENTERAL FEEDING FORMULAS MARKET IN 2022
  • 4.3 ENTERAL FEEDING FORMULAS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 19 MARKET IN CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
  • 4.4 ENTERAL FEEDING FORMULAS MARKET, BY REGION, 2020-2027
    • FIGURE 20 NORTH AMERICA WILL CONTINUE TO DOMINATE ENTERAL FEEDING FORMULAS MARKET TILL 2027

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 21 ENTERAL FEEDING FORMULAS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Benefits and cost-effectiveness of enteral over parenteral nutrition
      • 5.2.1.2 Rising preterm births fueling demand for enteral feeding formulas
    • FIGURE 22 US: TOTAL NUMBER OF PRETERM BIRTHS, 2010-2020
      • 5.2.1.3 Growing demand for enteral feeding in home care
      • 5.2.1.4 Rapid growth in geriatric population and disease prevalence
    • FIGURE 23 ESTIMATED DIABETIC POPULATION, BY REGION, 2019 VS. 2030 VS. 2040
    • FIGURE 24 GLOBAL CANCER INCIDENCE, 2015-2040
    • FIGURE 25 US: NUMBER OF PEOPLE WITH CHRONIC CONDITIONS, 1995-2030 (MILLION INDIVIDUALS)
    • TABLE 1 DRIVERS: IMPACT ANALYSIS
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Complications associated with enteral feeding
    • TABLE 2 COMPLICATIONS ASSOCIATED WITH ENTERAL FEEDING
      • 5.2.2.2 Lack of patient awareness
    • TABLE 3 RESTRAINTS: IMPACT ANALYSIS
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emergence of new products and innovation
      • 5.2.3.2 High growth opportunities in emerging countries
    • TABLE 4 OPPORTUNITIES: IMPACT ANALYSIS
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Insufficient reimbursements for enteral nutrition
      • 5.2.4.2 Dearth of skilled professionals
    • TABLE 5 CHALLENGES: IMPACT ANALYSIS
  • 5.3 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 6 PORTER'S FIVE FORCES ANALYSIS
    • 5.3.1 THREAT FROM NEW ENTRANTS
    • 5.3.2 THREAT FROM SUBSTITUTES
    • 5.3.3 BARGAINING POWER OF SUPPLIERS
    • 5.3.4 BARGAINING POWER OF BUYERS
    • 5.3.5 COMPETITIVE RIVALRY
  • 5.4 REGULATORY SCENARIO
    • 5.4.1 REGULATORY ANALYSIS
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 26 ENTERAL FEEDING FORMULAS MARKET: VALUE CHAIN ANALYSIS
  • 5.6 SUPPLY CHAIN ANALYSIS
    • FIGURE 27 ENTERAL FEEDING FORMULAS MARKET: SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM MARKET MAP
    • FIGURE 28 ENTERAL FEEDING FORMULAS MARKET: ECOSYSTEM MARKET MAP
  • 5.8 PRICING ANALYSIS
    • TABLE 7 AVERAGE PRICE OF ENTERAL FEEDING FORMULAS, IN USD (2021)
    • TABLE 8 AVERAGE SELLING PRICES OF ENTERAL FEEDING FORMULAS, 2017-2021 (USD)
  • 5.9 PATENT ANALYSIS
    • FIGURE 29 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR ENTERAL FEEDING FORMULA PATENTS (JANUARY 2011-OCTOBER 2021)
    • TABLE 9 INDICATIVE LIST OF PATENTS IN ENTERAL FEEDING FORMULAS MARKET
  • 5.10 KEY CONFERENCES AND EVENTS IN 2022-2023
    • TABLE 10 ENTERAL FEEDING FORMULAS MARKET: LIST OF CONFERENCES AND EVENTS
  • 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
    • FIGURE 30 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR ENTERAL FEEDING PRODUCTS
  • 5.12 KEY BUYING CRITERIA FOR END USERS
    • FIGURE 31 ENTERAL FEEDING FORMULAS MARKET: BUYING CRITERIA OF END USERS

6 ENTERAL FEEDING FORMULAS MARKET, BY STAGE

  • 6.1 INTRODUCTION
    • TABLE 11 ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020-2027 (USD MILLION)
  • 6.2 ADULTS
    • 6.2.1 INCREASED PREVALENCE OF CHRONIC DISEASES AND NEUROLOGICAL DISORDERS IN ADULT PATIENTS TO INCREASE MARKET SHARE
    • TABLE 12 ENTERAL FEEDING FORMULAS MARKET FOR ADULTS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 13 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR ADULTS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 14 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR ADULTS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 15 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR ADULTS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.3 PEDIATRICS
    • 6.3.1 GROWING DISEASE PREVALENCE IN PEDIATRIC PATIENTS DRIVING MARKET GROWTH
    • TABLE 16 ENTERAL FEEDING FORMULAS MARKET FOR PEDIATRICS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 17 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR PEDIATRICS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 18 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR PEDIATRICS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 19 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR PEDIATRICS, BY COUNTRY, 2020-2027 (USD MILLION)

7 ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT

  • 7.1 INTRODUCTION
    • TABLE 20 ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
  • 7.2 STANDARD FORMULAS
    • 7.2.1 EASE OF ACCESSIBILITY AND COST-EFFECTIVENESS WILL INCREASE MARKET GROWTH
    • TABLE 21 STANDARD ENTERAL FEEDING FORMULAS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 22 NORTH AMERICA: STANDARD ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 23 EUROPE: STANDARD ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 24 ASIA PACIFIC: STANDARD ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.3 DISEASE-SPECIFIC FORMULAS
    • TABLE 25 DISEASE-SPECIFIC ENTERAL FEEDING FORMULAS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 26 DISEASE-SPECIFIC ENTERAL FEEDING FORMULAS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 27 NORTH AMERICA: DISEASE-SPECIFIC ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 28 EUROPE: DISEASE-SPECIFIC ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 29 ASIA PACIFIC: DISEASE-SPECIFIC ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.3.1 DIABETIC FORMULAS
      • 7.3.1.1 Increased incidence of diabetes patients driving market growth
    • TABLE 30 DIABETIC FORMULAS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 31 NORTH AMERICA: DIABETIC FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 32 EUROPE: DIABETIC FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 33 ASIA PACIFIC: DIABETIC FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.3.2 RENAL FORMULAS
      • 7.3.2.1 Rise in patient population for chronic kidney disease to contribute to market growth
    • TABLE 34 RENAL FORMULAS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 35 NORTH AMERICA: RENAL FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 36 EUROPE: RENAL FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 37 ASIA PACIFIC: RENAL FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.3.3 HEPATIC FORMULAS
      • 7.3.3.1 Rise in obesity and alcohol consumption drive demand for hepatic formulas
    • TABLE 38 HEPATIC FORMULAS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 39 NORTH AMERICA: HEPATIC FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 40 EUROPE: HEPATIC FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 41 ASIA PACIFIC: HEPATIC FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.3.4 PULMONARY FORMULAS
      • 7.3.4.1 Rising disease prevalence to drive demand growth
    • TABLE 42 PULMONARY FORMULAS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 43 NORTH AMERICA: PULMONARY FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 44 EUROPE: PULMONARY FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 45 ASIA PACIFIC: PULMONARY FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.3.5 OTHER DISEASE-SPECIFIC FORMULAS
    • TABLE 46 OTHER DISEASE-SPECIFIC FORMULAS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 47 NORTH AMERICA: OTHER DISEASE-SPECIFIC FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 48 EUROPE: OTHER DISEASE-SPECIFIC FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 49 ASIA PACIFIC: OTHER DISEASE-SPECIFIC FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.4 PEPTIDE-BASED FORMULAS
    • 7.4.1 BENEFITS OF PEPTIDE-BASED FORMULAS OVER OTHER SEGMENTS POSITIVELY IMPACTING MARKET GROWTH
    • TABLE 50 PEPTIDE-BASED ENTERAL FEEDING FORMULAS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 51 NORTH AMERICA: PEPTIDE-BASED ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 52 EUROPE: PEPTIDE-BASED ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 53 ASIA PACIFIC: PEPTIDE-BASED ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.5 OTHER FORMULAS
    • TABLE 54 OTHER ENTERAL FEEDING FORMULAS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 55 NORTH AMERICA: OTHER ENTERAL FEEDING FORMULAS MARKET, 2020-2027 (USD MILLION)
    • TABLE 56 EUROPE: OTHER ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 57 ASIA PACIFIC: OTHER ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)

8 ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
    • TABLE 58 ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 8.2 ONCOLOGY
    • 8.2.1 GROWING INCIDENCE OF CANCER TO INCREASE MARKET SHARE
    • TABLE 59 NUMBER OF NEW CANCER PATIENTS IN AMERICA
    • TABLE 60 ENTERAL FEEDING FORMULAS MARKET FOR ONCOLOGY, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 61 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR ONCOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 62 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR ONCOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 63 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR ONCOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.3 GASTROENTEROLOGY
    • 8.3.1 INCREASING INCIDENCE OF GASTROINTESTINAL DISEASES TO DRIVE ADOPTION OF ENTERAL FEEDING FORMULAS
    • TABLE 64 INDICATIVE LIST OF DIGESTIVE DISEASES & DISORDERS REQUIRING ENTERAL FEEDING
    • TABLE 65 ENTERAL FEEDING FORMULAS MARKET FOR GASTROENTEROLOGY, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 66 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 67 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 68 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.4 NEUROLOGY
    • 8.4.1 HIGH BURDEN OF NEUROLOGICAL DISORDERS TO FUEL DEMAND FOR CLINICAL NUTRITION THERAPIES
    • TABLE 69 ENTERAL FEEDING FORMULAS MARKET FOR NEUROLOGY, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 70 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR NEUROLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 71 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR NEUROLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 72 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR NEUROLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.5 DIABETES
    • 8.5.1 USE OF ENTERAL FEEDING SYSTEMS IN DIABETICS HELPS PREVENT HYPERGLYCEMIA AND ASSOCIATED COMPLICATIONS
    • TABLE 73 ENTERAL FEEDING FORMULAS MARKET FOR DIABETES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 74 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR DIABETES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 75 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR DIABETES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 76 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR DIABETES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.6 OTHER APPLICATIONS
    • TABLE 77 ENTERAL FEEDING FORMULAS MARKET FOR OTHER APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 78 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 79 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 80 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)

9 ENTERAL FEEDING FORMULAS MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 81 ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.2 HOSPITALS
    • 9.2.1 GROWING CHRONIC AND INFECTIOUS DISEASE PREVALENCE DRIVES MARKET GROWTH
    • TABLE 82 ENTERAL FEEDING FORMULAS MARKET FOR HOSPITALS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 83 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR HOSPITALS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 84 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR HOSPITALS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 85 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR HOSPITALS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.3 LONG-TERM CARE FACILITIES
    • TABLE 86 ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 87 ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 88 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 89 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 90 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • 9.3.1 NURSING HOMES
      • 9.3.1.1 Need for nursing care in above-65 age group to drive market growth
    • TABLE 91 ENTERAL FEEDING FORMULAS MARKET FOR NURSING HOMES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 92 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR NURSING HOMES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 93 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR NURSING HOMES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 94 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR NURSING HOMES, BY COUNTRY, 2020-2027 (USD MILLION)
    • 9.3.2 ASSISTED LIVING FACILITIES
      • 9.3.2.1 Growth in chronic disease prevalence to support market growth
    • TABLE 95 ENTERAL FEEDING FORMULAS MARKET FOR ASSISTED LIVING FACILITIES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 96 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR ASSISTED LIVING FACILITIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 97 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR ASSISTED LIVING FACILITIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 98 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR ASSISTED LIVING FACILITIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • 9.3.3 HOME CARE AGENCIES & HOSPICES
      • 9.3.3.1 Limitations associated with home care to hamper market growth
    • TABLE 99 ENTERAL FEEDING FORMULAS MARKET FOR HOME CARE AGENCIES & HOSPICES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 100 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR HOME CARE AGENCIES & HOSPICES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 101 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR HOME CARE AGENCIES & HOSPICES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 102 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR HOME CARE AGENCIES & HOSPICES, BY COUNTRY, 2020-2027 (USD MILLION)

10 ENTERAL FEEDING FORMULAS MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 103 ENTERAL FEEDING FORMULAS MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 32 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET SNAPSHOT, 2021
    • TABLE 104 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 105 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020-2027 (USD MILLION)
    • TABLE 106 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 107 NORTH AMERICA: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 108 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 109 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020-2027 USD MILLION)
    • TABLE 110 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 Advanced healthcare system and availability of reimbursement for enteral nutrition to increase market growth
    • TABLE 111 US: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020-2027 (USD MILLION)
    • TABLE 112 US: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 113 US: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 114 US: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 115 US: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020-2027 USD MILLION)
    • TABLE 116 US: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Increasing incidence of chronic diseases such as diabetes and cancer supports market growth
    • TABLE 117 CANADA: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020-2027 (USD MILLION)
    • TABLE 118 CANADA: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 119 CANADA: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 120 CANADA: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 121 CANADA: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020-2027 USD MILLION)
    • TABLE 122 CANADA: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020-2027 (USD MILLION)
  • 10.3 EUROPE
    • TABLE 123 EUROPE: ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 124 EUROPE: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020-2027 (USD MILLION)
    • TABLE 125 EUROPE: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 126 EUROPE: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 127 EUROPE: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 128 EUROPE: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020-2027 USD MILLION)
    • TABLE 129 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.3.1 UK
      • 10.3.1.1 High incidence of target diseases to drive UK enteral feeding formulas market
    • TABLE 130 MACROINDICATORS FOR ENTERAL FEEDING FORMULAS MARKET IN UK
    • TABLE 131 UK: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020-2027 (USD MILLION)
    • TABLE 132 UK: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 133 UK: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 134 UK: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 135 UK: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020-2027 USD MILLION)
    • TABLE 136 UK: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.3.2 GERMANY
      • 10.3.2.1 Germany to overtake UK and dominate European market by 2027
    • TABLE 137 MACROINDICATORS FOR ENTERAL FEEDING FORMULAS MARKET IN GERMANY
    • TABLE 138 GERMANY: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020-2027 (USD MILLION)
    • TABLE 139 GERMANY: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 140 GERMANY: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 141 GERMANY: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 142 GERMANY: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020-2027 USD MILLION)
    • TABLE 143 GERMANY: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 Well-established healthcare system and strong government support contribute to market growth
    • TABLE 144 MACROINDICATORS FOR ENTERAL FEEDING FORMULAS MARKET IN FRANCE
    • TABLE 145 FRANCE: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020-2027 (USD MILLION)
    • TABLE 146 FRANCE: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 147 FRANCE: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 148 FRANCE: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 149 FRANCE: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020-2027 USD MILLION)
    • TABLE 150 FRANCE: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.3.4 ITALY
      • 10.3.4.1 Market growth attributed to growing geriatric population and need for nursing homes in Italy
    • TABLE 151 MACROINDICATORS FOR ENTERAL FEEDING FORMULAS MARKET IN ITALY
    • TABLE 152 ITALY: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020-2027 (USD MILLION)
    • TABLE 153 ITALY: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 154 ITALY: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 155 ITALY: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 156 ITALY: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020-2027 USD MILLION)
    • TABLE 157 ITALY: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.3.5 SPAIN
      • 10.3.5.1 Significant increase in patients opting for enteral nutrition to support market growth
    • TABLE 158 SPAIN: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020-2027 (USD MILLION)
    • TABLE 159 SPAIN: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 160 SPAIN: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 161 SPAIN: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 162 SPAIN: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020-2027 USD MILLION)
    • TABLE 163 SPAIN: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.3.6 REST OF EUROPE
    • TABLE 164 ROE: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020-2027 (USD MILLION)
    • TABLE 165 ROE: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 166 ROE: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 167 ROE: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 168 ROE: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020-2027 USD MILLION)
    • TABLE 169 ROE: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020-2027 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 33 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET SNAPSHOT
    • TABLE 170 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 171 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020-2027 (USD MILLION)
    • TABLE 172 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 173 ASIA PACIFIC: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 174 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 175 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020-2027 USD MILLION)
    • TABLE 176 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.4.1 JAPAN
      • 10.4.1.1 Rising geriatric population to drive market growth in Japan
    • TABLE 177 JAPAN: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020-2027 (USD MILLION)
    • TABLE 178 JAPAN: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 179 JAPAN: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 180 JAPAN: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 181 JAPAN: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020-2027 USD MILLION)
    • TABLE 182 JAPAN: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.4.2 CHINA
      • 10.4.2.1 Growing investment in healthcare infrastructure development to drive adoption of enteral feeding formulas
    • TABLE 183 CHINA: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020-2027 (USD MILLION)
    • TABLE 184 CHINA: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 185 CHINA: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 186 CHINA: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 187 CHINA: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020-2027 USD MILLION)
    • TABLE 188 CHINA: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.4.3 INDIA
      • 10.4.3.1 Increasing incidence of preterm births and cancer cases to drive market growth in India
    • TABLE 189 INDIA: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020-2027 (USD MILLION)
    • TABLE 190 INDIA: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 191 INDIA: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 192 INDIA: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 193 INDIA: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020-2027 USD MILLION)
    • TABLE 194 INDIA: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.4.4 REST OF ASIA PACIFIC
    • TABLE 195 ROAPAC: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020-2027 (USD MILLION)
    • TABLE 196 ROAPAC: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 197 ROAPAC: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 198 ROAPAC: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 199 ROAPAC: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020-2027 USD MILLION)
    • TABLE 200 ROAPAC: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020-2027 (USD MILLION)
  • 10.5 LATIN AMERICA
    • 10.5.1 ECONOMIC DEVELOPMENT, INCREASING HEALTHCARE ACCESS, AND GROWING DISEASE PREVALENCE TO DRIVE MARKET GROWTH
    • TABLE 201 LATIN AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020-2027 (USD MILLION)
    • TABLE 202 LATIN AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 203 LATIN AMERICA: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 204 LATIN AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 205 LATIN AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020-2027 USD MILLION)
    • TABLE 206 LATIN AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020-2027 (USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND HEALTH INSURANCE PENETRATION TO SUPPORT MARKET GROWTH
    • TABLE 207 MIDDLE EAST AND AFRICA: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020-2027 (USD MILLION)
    • TABLE 208 MIDDLE EAST AND AFRICA: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 209 MIDDLE EAST AND AFRICA: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 210 MIDDLE EAST AND AFRICA: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 211 MIDDLE EAST AND AFRICA: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020-2027 USD MILLION)
    • TABLE 212 MIDDLE EAST AND AFRICA: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020-2027 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • FIGURE 34 KEY PLAYER STRATEGIES IN ENTERAL FEEDING FORMULAS MARKET, 2019-2022
  • 11.3 MARKET SHARE ANALYSIS
    • FIGURE 35 ENTERAL FEEDING FORMULAS MARKET: MARKET SHARE ANALYSIS, 2021 (TOP FIVE PLAYERS)
    • TABLE 213 ENTERAL FEEDING FORMULAS MARKET: DEGREE OF COMPETITION
  • 11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 36 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN ENTERAL FEEDING FORMULAS MARKET
  • 11.5 COMPANY EVALUATION QUADRANT
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • FIGURE 37 ENTERAL FEEDING FORMULAS MARKET: COMPANY EVALUATION QUADRANT, 2021
  • 11.6 COMPETITIVE BENCHMARKING
    • 11.6.1 COMPANY FOOTPRINT ANALYSIS
    • FIGURE 38 COMPANY FOOTPRINT ANALYSIS
    • 11.6.2 COMPANY PRODUCT FOOTPRINT
    • TABLE 214 PRODUCT PORTFOLIO ANALYSIS
    • 11.6.3 COMPANY REGIONAL FOOTPRINT
    • TABLE 215 REGIONAL REVENUE MIX
      • 11.6.3.1 COMPETITIVE BENCHMARKING
    • TABLE 216 ENTERAL FEEDING FORMULAS MARKET: DETAILED LIST OF KEY START-UPS/SMES
    • TABLE 217 ENTERAL FEEDING FORMULAS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (START-UPS/SMES)
  • 11.7 COMPETITIVE SCENARIO AND TRENDS
    • TABLE 218 PRODUCT LAUNCHES & APPROVALS, JANUARY 2019-JULY 2022
    • TABLE 219 DEALS, JANUARY 2019-JULY 2022
    • TABLE 220 OTHER DEVELOPMENTS, JANUARY 2019-JULY 2022

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 12.1.1 ABBOTT
    • TABLE 221 ABBOTT: BUSINESS OVERVIEW
    • FIGURE 39 ABBOTT: COMPANY SNAPSHOT (2021)
    • 12.1.2 NESTLE
    • TABLE 222 NESTLE: BUSINESS OVERVIEW
    • FIGURE 40 NESTLE: COMPANY SNAPSHOT (2021)
    • 12.1.3 DANONE S.A.
    • TABLE 223 DANONE: BUSINESS OVERVIEW
    • FIGURE 41 DANONE: COMPANY SNAPSHOT (2021)
    • 12.1.4 FRESENIUS KABI
    • TABLE 224 FRESENIUS KABI: BUSINESS OVERVIEW
    • FIGURE 42 FRESENIUS KABI: COMPANY SNAPSHOT (2021)
    • 12.1.5 B. BRAUN MELSUNGEN AG
    • TABLE 225 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW
    • FIGURE 43 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT (2021)
    • 12.1.6 OTSUKA HOLDINGS CO., LTD.
    • TABLE 226 OTSUKA HOLDINGS CO., LTD.: BUSINESS OVERVIEW
    • FIGURE 44 OTSUKA HOLDINGS CO., LTD.: COMPANY SNAPSHOT (2021)
    • 12.1.7 NUTRITIONAL MEDICINALS, LLC
    • TABLE 227 NUTRITIONAL MEDICINALS, LLC: BUSINESS OVERVIEW
    • 12.1.8 KATE FARMS
    • TABLE 228 KATE FARMS: BUSINESS OVERVIEW
    • 12.1.9 MEDTRITION INC.
    • TABLE 229 MEDTRITION INC.: BUSINESS OVERVIEW
    • 12.1.10 VICTUS, INC.
    • TABLE 230 VICTUS, INC.: BUSINESS OVERVIEW
    • 12.1.11 GLOBAL HEALTH PRODUCTS, INC.
    • TABLE 231 GLOBAL HEALTH PRODUCTS, INC.: BUSINESS OVERVIEW
    • 12.1.12 MEIJI HOLDINGS
    • TABLE 232 MEIJI HOLDINGS CO., LTD.: BUSINESS OVERVIEW
    • FIGURE 45 MEIJI HOLDINGS CO., LTD.: COMPANY SNAPSHOT (2021)
    • 12.1.13 RECKITT BENCKISER GROUP
    • TABLE 233 RECKITT BENCKISER GROUP: BUSINESS OVERVIEW
    • FIGURE 46 RECKITT BENCKISER GROUP: COMPANY SNAPSHOT (2021)
  • 12.2 OTHER COMPANIES
    • 12.2.1 HORMEL FOODS CORPORATION
    • 12.2.2 DERMARITE INDUSTRIES
    • 12.2.3 MEDLINE INDUSTRIES, LP
    • 12.2.4 REAL FOOD BLENDS
    • 12.2.5 AJINOMOTO CAMBROOKE, INC.
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 AVAILABLE CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS